You are here

Company Monitoring Page for Argenx

job ratings for Argenx

08/05/23

industry:

job title:

TBM

company:

Argenx

job rating:

1

Horrible leadership especially in Rebecca M., Unrealistic sales goals for rare disease, weak bonus payout, we are literally paying our speakers to prescribe Vyvgart, our HUB sucks, our field reimbursement team was recruited straight from Wal-Mart, RBDs are clueless, oh and our CEO is a freak weirdo.

latest headlines for company on cafepharma

Argenx' Vyvgart launch in CIDP picks up as the company barrels toward 10 indications by 2030

Fierce Pharma

Sun, 11/3/24 - 10:13 pm

Tags:

Argenx, CIDP, Vygart

Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing

Fierce Pharma

Thu, 09/19/24 - 11:06 am

Tags:

artificial intelligence, Bayer, Daiichi Sankyo, Argenx

J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

Fierce Biotech

Mon, 07/1/24 - 11:23 am

Tags:

JNJ, nipocalimab, myasthenia gravis, clinical trials, UCB, Argenx

Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch

Fierce Pharma

Fri, 05/10/24 - 11:37 am

Tags:

Argenx, myasthenia gravis, Vyvgart

FDA starts review of Argenx drug in rare disease CIDP

Pharmaphorum

Tue, 02/20/24 - 11:01 am

Tags:

Argenx, Vygart Hytrulo, CIDP, FDA

Argenx dealt another blow as Vyvgart Hytrulo fails again

Pharmaphorum

Wed, 12/20/23 - 09:28 am

Tags:

Argenx, Vyvgart, clinical trials, Vyvgart Hytrulo, pemphigus vulgaris

On blockbuster path, Argenx's red-hot Vyvgart comes up short in thrombocytopenia trial

Fierce Pharma

Wed, 11/29/23 - 12:02 pm

Tags:

Argenx, Vyvgart, thrombocytopenia, clinical trials

Argenx's Vyvgart gains commercial momentum in gMG as company plots expansion into new uses

Fierce Pharma

Wed, 11/1/23 - 11:04 am

Tags:

Argenx, Vygart, myasthenia gravis

Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product

Fierce Pharma

Tue, 07/18/23 - 10:29 am

Tags:

Argenx, Vyvgart, clinical trials, CIDP

Unpartnered assets: on the shelf or hidden treasure?

EP Vantage

Thu, 06/15/23 - 09:54 am

Tags:

R&D, ALX Oncology, Argenx, Ascendis Pharma, Cytokinetics, Karuna Therapeutics, Madrigal Pharmaceuticals, Protagonist Therapeutics, Prothena, Ultragenyx Pharmaceutical, Unique Pharma, Ventyx Biosciences

Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas

Fierce Biotech

Mon, 04/17/23 - 11:19 am

Tags:

Genmab, Argenx, antibody discovery, drug discovery, cancer, immunology

OncoVerity eyes cusatuzumab development in AML after licensing rights

Pharmaceutical Technology

Tue, 03/28/23 - 10:41 pm

Tags:

OncoVerity, Argenx, AML, cusatuzumab

Biotech heads towards big catalysts

EP Vantage

Tue, 03/28/23 - 10:24 am

Tags:

biotech, clinical trials, Alnylam Pharmaceuticals, Arcus Biosciences, Argenx, Arrowhead Pharmaceuticals, Axsome Therapeutics, Bavarian Nordic, FibroGen, Gilead Sciences, Incyte, Morphic Therapeutic, PTC Therapeutics, Syndax Pharmaceuticals, Travere Therapeutics, Vaxcyte

The world needs Garp, according to Abbvie

EP Vantage

Fri, 02/10/23 - 10:20 am

Tags:

AbbVie, GARP, Argenx, R&D

Biotech’s key upcoming clinical results

EP Vantage

Tue, 12/20/22 - 10:27 am

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

BioPharma Dive

Mon, 12/12/22 - 10:56 pm

Tags:

ASH 2022, JNJ, talquetamab, Multiple Myeloma, Argenx, Bluebird Bio, Vyvgart, ITP

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease

Fierce Pharma

Sun, 12/11/22 - 01:32 pm

Tags:

ASH 2022, ITP, efgartigimod, Argenx

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Benzinga

Wed, 11/30/22 - 10:47 am

Tags:

Bluebird Bio, priority review vouchers, FDA, Argenx

Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic

BioSpace

Tue, 11/22/22 - 04:30 pm

Tags:

Argenx, FDA, priority reviews, myasthenia gravis, efgartigimod

Pages

last 30 twitter posts